Aclaris Therapeutics (NASDAQ:ACRS) received 6 analyst ratings in the last quarter, with an average 12-month price target of $19.17, a decline of 11.54% from the prior average. Ratings include 2 bullish, 2 somewhat bullish, and 2 indifferent. Notable actions include Stifel's Alex Thompson lowering the price target from $2.00 to $1.00 and HC Wainwright & Co.'s Raghuram Selvaraju lowering from $43.00 to $9.00. Aclaris focuses on immuno-inflammatory diseases and earns most revenue from its contract research segment. It has a low market cap, a significant revenue decline of -51.19%, a high net margin of -315.24%, an ROE of -17.41%, an ROA of -12.89%, and no debt.